Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Katharina L. Kopp"'
Autor:
Inés Lecoq, Katharina L. Kopp, Marion Chapellier, Panagiotis Mantas, Evelina Martinenaite, Maria Perez-Penco, Lars Rønn Olsen, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
CCL22 is a macrophage-derived immunosuppressive chemokine that recruits regulatory T cells through the CCL22:CCR4 axis. CCL22 was shown to play a key role in suppressing anti-cancer immune responses in different cancer types. Recently, we showed that
Externí odkaz:
https://doaj.org/article/4deb28186bcd4fa28e4ce8cd2df20145
Autor:
Mads Hald Andersen, Souvik Dey, Erika Sutanto-Ward, Katharina L Kopp, James DuHadaway, Arpita Mondal, Dema Ghaban, Inés Lecoq, Mai-Britt Zocca, Lauren M F Merlo, Laura Mandik-Nayak, Ayako Wakatsuki Pedersen, Alexander J Muller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpre
Externí odkaz:
https://doaj.org/article/85b92312e7ef499e81e377e49eedf1d5
Autor:
Evelina Martinenaite, Annalisa Adamo, Stine Emilie Weis-Banke, Katharina L. Kopp, Maria Perez-Penco, Stefano Ugel, Marion Chapellier, Vincenzo Bronte, Mie Linder Hübbe, Cristina Frusteri, Marco Carretta, Mia Aaboe Jørgensen, Mai-Britt Zocca, Francesco De Sanctis, Ayako Wakatsuki Pedersen, Manuela Iezzi, Mads Hald Andersen, Daniel Hargbøll Madsen
Publikováno v:
Cancer immunology research. 9(11)
Expression of the L-arginine catabolizing enzyme arginase 1 (ARG1) is a central immunosuppressive mechanism mediated by tumor-educated myeloid cells. Increased activity of ARG1 promotes the formation of an immunosuppressive microenvironment and leads
Autor:
Souvik Dey, Inés Lecoq, James B. DuHadaway, Erika Sutanto-Ward, Arpita Mondal, Katharina L. Kopp, Mads Hald Andersen, Mai-Britt Zocca, Alexander J. Muller, Ayako Wakatsuki Pedersen
Publikováno v:
E-Poster Presentations.
Background Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-catabolizing enzyme that contributes to immunoregulation at many levels, including suppressing effector T cells and inducing/activating regulatory T cells. Thus far, several therapeutic
Autor:
R Christensen, Ayako Wakatsuki Pedersen, Inés Lecoq, Katharina L. Kopp, Mads Hald Andersen, Evelina Martinenaite
Publikováno v:
E-Poster Presentations.
Background CCL22 is a macrophage-derived chemokine that exerts immunosuppressive functions by the recruitment of regulatory T cells (Treg) through the CCL22/CCR4 axis. It has been described to play a key role in the suppression of anti-cancer immunit
Autor:
Souvik, Dey, Erika, Sutanto-Ward, Katharina L, Kopp, James, DuHadaway, Arpita, Mondal, Dema, Ghaban, Inés, Lecoq, Mai-Britt, Zocca, Lauren M F, Merlo, Laura, Mandik-Nayak, Mads Hald, Andersen, Ayako Wakatsuki, Pedersen, Alexander J, Muller
Publikováno v:
Journal for Immunotherapy of Cancer
Background The tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpre
Autor:
James B. DuHadaway, Erika Sutanto-Ward, Dema Ghaban, Lauren M.F. Merlo, Arpita Mondal, Mads Hald Andersen, Ayako Wakatsuki Pedersen, Laura Mandik-Nayak, Souvik Dey, Katharina L. Kopp, Inés Lecoq, Alexander J. Muller, Mai-Britt Zocca
Publikováno v:
Dey, S, Sutanto-Ward, E, Kopp, K L, Duhadaway, J, Mondal, A, Ghaban, D, Lecoq, I, Zocca, M B, Merlo, L M F, Mandik-Nayak, L, Andersen, M H, Pedersen, A W & Muller, A J 2020, ' Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 + and CD4 + T-cell-mediated antitumor immunity and enhanced anti-PD1 responses ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 2, 2020000605 . https://doi.org/10.1136/jitc-2020-000605
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
BackgroundThe tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which subverts T-cell immunity at multiple levels, is itself subject to inherent T-cell reactivity. This intriguing deviation from central tolerance has been interpret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24213c5586cc584ecdd188e8c7c16e98
https://curis.ku.dk/ws/files/258770834/e000605.full.pdf
https://curis.ku.dk/ws/files/258770834/e000605.full.pdf
Autor:
Mariusz A. Wasik, Lars Jønson, Charlotte M. Bonefeld, Lise Mette Rahbek Gjerdrum, Elisabeth Ralfkiaer, Niels Ødum, Ulrik Ralfkiaer, Anders Woetmann, Katharina L. Kopp, Carsten Geisler, Qian Zhang, Sally Dabelsteen, Louise Christensen, Britt Lauenborg
Publikováno v:
Oncotarget
Europe PubMed Central
Scopus-Elsevier
Europe PubMed Central
Scopus-Elsevier
// Britt Lauenborg 1 , Louise Christensen 1 , Ulrik Ralfkiaer 2 , Katharina L. Kopp 1 , Lars Jonson 3 , Sally Dabelsteen 4 , Charlotte M. Bonefeld 1 , Carsten Geisler 1 , Lise Mette R. Gjerdrum 5 , Qian Zhang 6 , Mariusz A. Wasik 6 , Elisabeth Ralfki
Autor:
Rikke Christensen, Mads Hald Andersen, Evelina Martinenaite, Mai-Britt Zocca, Inés Lecoq, Ayako Wakatsuki Pedersen, Katharina L. Kopp
Publikováno v:
Cancer Research. 79:5020-5020
CCL22 is a macrophage-derived chemokine that exerts immunosuppressive functions by the recruitment of regulatory T cells (Tregs) through the CCL22/CCR4 axis. It is expressed by cells in the tumor microenvironment (TME) in many different cancer tissue
Autor:
Claudia Nastasi, Tengpeng Hu, Andreas Willerslev-Olsen, Edda Blümel, Terkild B. Buus, Christina Friese, Thorbjørn Krejsgaard, Sergei B. Koralov, Mariusz A. Wasik, Niels Ødum, Jenny L. Persson, Sarah L. Mathiasen, Maria Gluud, Özcan Met, David L. Petersen, Katharina L. Kopp, Linda Kubat, Anders Woetmann, Simon Fredholm, Charlotte M. Bonefeld, Lise M. Lindahl, Jürgen C. Becker, Carsten Geisler, Lars Iversen
Publikováno v:
Fredholm, S, Willerslev-Olsen, A, Met, Ö, Kubat, L, Gluud, M, Mathiasen, S L, Friese, C, Blümel, E, Petersen, D L, Hu, T, Nastasi, C, Lindahl, L M, Buus, T B, Krejsgaard, T, Wasik, M A, Kopp, K L, Koralov, S B, Persson, J L, Bonefeld, C M, Geisler, C, Woetmann, A, Iversen, L, Becker, J C & Odum, N 2018, ' SATB1 in Malignant T Cells ', Journal of Investigative Dermatology, vol. 138, no. 8, pp. 1805-1815 . https://doi.org/10.1016/j.jid.2018.03.1526
Deficient expression of Suppressor Special AT-rich Binding-1 (SATB1) hampers thymocyte development and results in inept T cell lineages. Recent data implicate dysregulated SATB1 expression in the pathogenesis of mycosis fungoides (MF), the most frequ